Latest immunotherapy news
Early Use of Higher-Efficacy Therapies Recommended for Moderate-to-Severe Crohn Disease
posted November 26th
by modernClinician Editorial Team
by modernClinician Editorial Team
FDA Approves Darzalex Faspro for High-Risk Smoldering Multiple Myeloma
posted November 13th
by modernClinician Editorial Team
by modernClinician Editorial Team
Dupilumab Reduces Mucus Plug Scores With Moderate-to-Severe Asthma
posted November 3rd
by modernClinician Editorial Team
by modernClinician Editorial Team
COVID Vaccine Before ICI Initiation Tied to Increased Survival in Patients With Cancer
posted October 28th
by modernClinician Editorial Team
by modernClinician Editorial Team
Editor's Recommendations
Thymic Radiation Linked to Worse Outcomes in Patients With NSCLC 
All-Cause Mortality Elevated for Adult Five-Year Survivors of Hodgkin Lymphoma 
Preoperative Chemo + Immunotherapy Combo Shrinks Head, Neck Cancer Tumors 
Achieving PSA <0.2 ng/mL Improves Survival in Metastatic Castration-Sensitive Prostate Cancer Related Articles
Cretostimogene Promising for High-Risk, Non-Muscle-Invasive Bladder Cancer 
Omalizumab, Multiallergen OIT Both Viable for Multifood Allergy Treatment 
Enfortumab Vedotin-Pembrolizumab More Effective for MIBC Than Cisplatin-Gemcitabine 
Indefinite-Duration Maintenance Therapy No Better Than Fixed-Duration Therapy in Multiple Myeloma Monthly Specialist Briefings
Stay Connected
